44 results about "Inflammatory marker" patented technology

The invention is applicable to the technical field of biological detection, provides a fluorescence immunochromatography detection method based on monatomic nano-enzyme enhancement, and particularly relates to two application forms: in the first form, a detection signal enhanced fluorescence immunochromatography detection card and a sample diluent containing a monatomic nano-enzyme are involved; in the second form, the invention relates to a fluorescence immunochromatography detection card with enhanced detection signals, and a sample pad of the detection card is obtained by soaking a sample pad treatment solution containing a monatomic nano-enzyme solution. The two application forms both relate to a monatomic nano-enzyme solution, and the solution is composed of monatomic nano-enzyme, bio-enzyme composite microspheres, a protective agent, a surfactant, a thickening agent and a preservative. The monatomic nano enzyme is composed of an atomic-scale dispersed metal active center and a carrier material. When the method is used for detecting myocardial and inflammatory markers, the limit of quantitation can reach the pg / mL level, the detection linear range can span three orders of magnitude, and the clinical examination use requirements can be met. The kit can be applied to rapid quantitative detection of myocardial and inflammatory markers, has the advantages of high sensitivity, rapidness, convenience and high efficiency, and provides an auxiliary diagnosis basis for early screening of myocardial infarction, heart failure and infection related diseases.

The invention discloses a post-stroke depression risk prediction system based on cerebral small vascular diseases and inflammatory markers, and relates to the technical field of computer-aided engineering, the post-stroke depression risk prediction system comprises: a data acquisition module acquires CSVD image data, serum inflammatory markers and clinical baseline information; the data preprocessing module processes image denoising registration, fills up marker missing values and encodes clinical information; the CSVD feature extraction module extracts image omics features and quantifies severity; the inflammation marker module calculates statistical characteristics and inflammation intensity; the multi-dimensional fusion module integrates features and eliminates redundancy; the risk prediction module is trained by using an improved attention CNN-LSTM model; the result output module visualizes risk and intervention suggestions; the model dynamic optimization module updates parameters by incremental learning. According to the method, multi-source key data are integrated, the prediction accuracy and generalization ability are improved, clinical interpretation and dynamic adaptability are achieved, early recognition of post-stroke depression is assisted, and patient prognosis is improved.

A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

This invention relates to the field of medical information management technology, including an AI-based endometriosis management system. The system comprises a thickness dynamic monitoring module, an inflammation level assessment module, a lesion spread analysis module, a periodic lesion tracking module, and a disease progression analysis module. In this invention, AI is used to segment ultrasound image data, enabling dynamic monitoring of lesion areas. Lesion boundaries are extracted, and changes in local inflammatory marker concentrations are calculated, making the screening of abnormal inflammatory areas more accurate and enabling early identification of lesion development. The tracking of periodic lesions, combined with analysis of lesion contour changes and area increases / decreases, enhances the quantitative control of disease progression. The future development trend of lesions, combined with the calculation of periodic inflammatory pathways, makes the prediction of disease evolution more consistent with physiological changes. Multi-dimensional lesion analysis combined with AI intelligent calculation expands the diagnosis and treatment of endometriosis from static assessment to dynamic trend prediction, improving the adaptability of personalized treatment plans.

The application discloses a kind of elderly hip fracture surgery perioperative adverse event real-time monitoring system and method, it is related to perioperative monitoring technical field.The method includes: real-time acquisition perioperative monitoring data, carries out data pre-processing, and extracts benchmark feature;Identify the decline segment of cerebral oxygen saturation below benchmark feature, jointly assess the decline amplitude and persistence, obtain the weak trend characterization of brain oxygen;Analysis of the relative change characteristics of serum inflammatory markers, form the weak trend characterization of inflammation;Assess the deviation degree of vital signs relative to benchmark, obtain the vital signs fluctuation characterization, and further judge the delirium precursor risk, output risk prompt;Visual display various weak trend characterizations and delirium precursor risk, link label risk trigger information and contribution source.The present application solves the technical problems that the prior art is difficult to extract and identify early weak abnormal trend in perioperative multi-source physiological signals.

The invention discloses a detection method of inflammatory marker protein. According to the method, the micro-fluidic chip with a sample loading area, a buffer treatment area, a sample channel and a detection area is prepared on filter paper through wax printing; chitosan is preset in the sample loading area and is used for treating a sample, and bromothymol blue is fixed in the detection area and is used as a pH indicator. During detection, a sample is driven by a phosphate buffer solution with the pH value of 6.0 to flow to a detection area through capillary action, the C-reactive protein and the indicator are subjected to non-specific binding, so that the color of the detection area is changed from yellow to green, the length of a green developing signal is in direct proportion to the concentration of the CRP, and quantitative detection can be realized by measuring the length. The method does not need an antibody, is low in cost, is simple and convenient to operate, can complete detection within 15 minutes, has the detection limit of 1.56 ng / ml and the linear range of 5-25 ng / ml, and is suitable for rapid screening and field detection of basic medical institutions.

The present embodiments provide a plant-based lipid composition comprising high concentrations of long-chain omega-3 fatty acids, typically as fatty acid esters, comprising DPA, DTA, ETA, or ETrA, optionally with OA or ALA. These enriched lipid compositions have improved stability, and offer a sustainable source for these long-chain omega-3 fatty acids. In some embodiments, these enriched lipid compositions show enhanced modulation of inflammatory markers, such as inhibition of inflammatory cytokines, and offer nutritional or therapeutic value..

The invention discloses a system and a method for dynamically identifying vulnerable plaques of an intravascular ultrasonic image. According to the system, plaque evolution information of continuous IVUS image frames is extracted by constructing a feature extraction module based on a space-time convolutional neural network; combining limited OCT annotation data through a transfer learning model; the blood flow wall shear force and the inflammatory marker IL-6 are fused in a plaque rupture risk prediction matrix, and a new mathematical calculation model is provided to predict the plaque risk. The system supports real-time analysis in an interventional operation and automatically marks a high-risk plaque area, and the vulnerable plaque detection sensitivity can reach 94% or above. The hardware architecture comprises an image acquisition unit, a deep learning calculation module and a labeling interaction module; the software architecture comprises a plaque recognition engine, a shear force calculation module, a biological data fusion interface and the like. The system has the advantages of being easy and convenient to operate, high in real-time performance, high in accuracy and the like, and an efficient intraoperative plaque risk assessment tool is provided for interventional therapy.

The invention provides an EP300 detection preparation and application of EP300 in a product for treating rheumatoid arthritis, and relates to the technical field of biological medicines. The rheumatoid arthritis symptom is relieved by inhibiting EP300 gene expression, after EP300 is knocked down in human THP-1-derived macrophages, H3K18 lactylation expression is reduced, and after EP300 is knocked down in human THP-1-derived macrophages, EP300 and human synovial cells are co-cultured, so that the human THP-1-derived macrophages are subjected to H3K18 lactylation expression is reduced, the human THP-1-derived macrophages are subjected to H3K18 lactylation expression is reduced, and the human THP-1-derived macrophages are obtained. Through the crosstalk effect between human THP-1-derived macrophages and human synovial cells, the expression of inflammatory markers MMP3 and Fibronectin in the synovial cells can be remarkably inhibited, compared with a model group, the proliferation capacity of the synovial cells is weakened, a potential treatment target is provided for treating rheumatoid arthritis, and the application has the advantages that the application is easy to popularize and use, and the application has a wide application prospect. The pathogenesis of rheumatoid arthritis is perfected, and hope is brought to research and development of novel biomarkers for early diagnosis, targeted therapy and prognosis evaluation of rheumatoid arthritis.

The invention relates to the technical field of skin care, and particularly discloses a composition with a periorbital care effect and a preparation method thereof. According to the invention, Tieguanyin and lethariella cladonioides extracts are used as core active components, and nicotinamide is compounded as a synergistic component. The Tieguanyin extract and the lethariella cladonioides extract synergistically exert the effects of resisting oxidation, resisting inflammation and preventing melanin accumulation, and nicotinamide intervenes melanin transport and metabolism through multiple ways. All the components generate a remarkable synergistic effect, the active oxygen level and inflammatory marker expression can be synchronously reduced on the cellular level, synthesis and accumulation of melanin can be effectively reduced, and the anti-inflammatory and soothing characteristics are shown. Intracellular oxidative stress can be remarkably inhibited through synergism of the components, and the composition has wide application in skin care products, especially eye care products.

A sprayable polymeric scaffold composition for localized anti-inflammatory therapy is disclosed. The composition comprises lipid nanorods encapsulating inflammasome inhibitors, a thermogelling agent, and a thickening agent. The lipid nanorods, which can be formed using pyridoxine dipalmitate and DSPE-PEG (2000) carboxylic acid, inhibit NLRP3 and AIM2 inflammasomes, reducing inflammation. The thermogelling agent, such as poloxamer 407, enables the composition to transition from a fluid sol state at room temperature to a semi-solid gel state at body temperature, forming a localized gel film upon topical application. The thickening agent, such as mucin, enhances viscosity and provides additional anti-inflammatory effects. The composition delivers sustained release of encapsulated inhibitors, effectively reducing inflammatory markers and symptoms in conditions such as psoriasis. The sprayable scaffold offers a novel, localized treatment platform with improved skin penetration, ease of administration, and reduced systemic side effects.

This invention relates to methods and compositions useful in subjects suffering from or at risk of suffering from sepsis or other dysregulated inflammatory responses. It has been demonstrated that the CETP inhibitor obicetrapib not only preserved or increased HDL-C and Apo A1 levels, but also reduced an important pro-inflammatory marker, IL-1β, and significantly increased survival, relative to placebo, in a suitable sepsis mouse model. Thus, broadly stated, the present invention concerns the use of CETP inhibitors in the prevention, treatment, management or amelioration of sepsis, or other dysregulated inflammatory responses in a subject.

The invention provides a process for preparing a Biochanin A (BCA)-loaded hydroxypropyl methyl cellulose (HPMC) hydrogel aimed at promoting wound healing in diabetic patients. The hydrogel is prepared by dispersing HPMC in distilled water, followed by dissolving BCA into the mixture with continuous stirring, then storing under refrigeration. The therapeutic potential of Biochanin A (BCA) in promoting wound healing, is evaluated in rats induced with diabetes. The results showed that the BCA-loaded hydrogel accelerates diabetic wound repair by boosting antioxidant defenses via upregulating Nrf2 and related enzymes, suppressing inflammatory markers such as IL-1β, IL-6, TNF-α, COX-2, and TLR4, and stimulating angiogenesis through increased expression of TGF-β1, VEGF-A, and PDGFR. It promotes faster wound contraction, re-epithelialization, collagen deposition, granulation tissue formation, and neovascularization, potentially reducing the risk of complications like limb amputation. The invention offers a promising therapeutic approach for treating chronic diabetic wounds with improved healing outcomes.

A method to assess the disease status, determine the mean / average control of the disease and monitor the compliance to treatment over a period of time of a respiratory disease, comprising of predicting the degree of airway inflammation and disease activity by measuring the inflammatory markers, evaluating the mucosal integrity / damage by measuring the moisture levels of the exhaled air, evaluating the breathing function and obstruction by measuring the FEV1 value, and evaluating the symptom control by determining the COPD Score.

Anti-inflammatory topical compositions are disclosed in which niacinamide and polylysine dendrimer synergistically reduce the release of inflammatory markers (e.g., IL-8) from skin cells. Also disclosed are anti-inflammatory topical compositions in which polylysine dendrimer and various plant extracts reduce the release of inflammatory markers (e.g., IL-8) from skin cells. The pro-oxidative activity of polylysine dendrimer may be reduced by including an antioxidant (e.g., tocopherol and / or tocopheryl acetate) to an anti-inflammatory topical composition. Anti-inflammatory topical compositions comprising polylysine dendrimer and niacinamide and / or plant extracts (e.g., aloe vera extract, edelweiss extract, scuatline, etc.) may be used for treating inflammatory skin conditions (e.g., acne) by reducing the release of inflammatory markers (e.g., IL-8) from skin cells.

The invention relates to an electrochemiluminescence sensor based on an intelligent controlled release-interface capture-self-enhancement mechanism and application of the electrochemiluminescence sensor in procalcitonin detection, and belongs to the technical field of electrochemiluminescence detection. Controllable release of signal molecules is achieved by packaging terpyridyl ruthenium through ZIF-8, meanwhile, a DNA layer rich in guanine is modified on an electrode interface, and the layer can serve as a nano trap to efficiently capture the signal molecules and can also serve as a co-reactant to achieve signal amplification. A DNA strand displacement reaction is utilized to regulate and control a target response release process, and detection is realized according to a quantitative relationship between the concentration of procalcitonin and an electrochemical luminescence signal. A labeling recovery method verifies that the recovery rate of the sensor in a human serum sample reaches 100.6-103.6%, good accuracy and precision are shown, and a reliable platform is provided for clinical detection of inflammatory markers.

The invention discloses an application of KL-6 alone or in combination with other immune inflammation markers in complex silicosis recognition and lung function injury evaluation. The invention firstly discloses application of KL-6 in preparation of a product for complex silicosis identification and lung function injury evaluation. The invention further discloses application of the KL-6 combined with other immune inflammation markers in preparation of products for complex silicosis recognition and lung function injury evaluation. According to the invention, KL-6 is taken as a core, LDH and ESR are combined to construct a diagnosis scheme, and complex silicosis and dust exposed persons or simple silicosis can be distinguished; meanwhile, KL-6 is in significant negative correlation with lung function parameters and can assist in evaluating the severity of diseases and the condition of lung function impairment. The method is rapid and accurate in diagnosis, easy and convenient to operate, controllable in cost, capable of achieving batch detection, suitable for health monitoring of high-risk occupational people and capable of providing efficient technical support for early recognition of complex silicosis, lung function injury evaluation and clinical decision making.

The invention relates to the technical field of re-admission risk dynamic prediction methods, in particular to an AECOPD disease and symptom combined re-admission risk dynamic prediction method based on multi-algorithm fusion, which comprises the following data: (1) multi-source heterogeneous data: acquiring western medicine clinical data of a patient through a hospital information system (HIS); comprise lung function indexes, arterial blood gas analysis, inflammatory markers, the number of complications, the previous hospitalization frequency and the like; (2) dynamic monitoring of data: acquiring daily oxyhemoglobin saturation, heart rate variability and six-minute walking distance after hospital discharge through a wearable device; according to the AECOPD disease and symptom combined re-admission risk dynamic prediction method based on multi-algorithm fusion, on the basis of syndrome data of four diagnosis instruments of traditional Chinese medicine, AECOPD disease and symptom characteristics and a re-admission risk dynamic prediction method are fused, a disease and symptom fusion characteristic engineering system is constructed, deep coupling of western medicine and traditional Chinese medicine characteristics is achieved, and a traditional prediction model data barrier is broken through; by introducing spatial-temporal feature dynamic construction, complete-cycle description of a disease process is realized, and a multi-algorithm fusion architecture is innovated.

This invention discloses a traditional Chinese medicine composition for treating ulcerative colitis, its preparation method, combined drugs, and applications. The traditional Chinese medicine composition for treating ulcerative colitis of this invention is made from the following raw materials in parts by weight: Astragalus membranaceus 13-26 parts, Lonicera japonica 10-20 parts, Sargentodoxa cuneata 10-20 parts, Prunus mume 8-16 parts, Agrimonia pilosa 8-16 parts, Allium macrostemon 6-12 parts, Platycodon grandiflorus 6-12 parts, Coptis chinensis 3-6 parts, and Panax notoginseng powder 1-3 parts. An animal model of ulcerative colitis was constructed using DSS induction, and the results showed that the traditional Chinese medicine composition of this invention has a certain therapeutic effect on ulcerative colitis. Clinical studies showed that the traditional Chinese medicine composition of this invention, used in combination with mesalazine enteric-coated tablets, can reduce the modified Mayo score and serum inflammatory markers in patients with active ulcerative colitis, improve colonic mucosal inflammation and gastrointestinal symptoms, and effectively treat active ulcerative colitis of the damp-heat type.

The invention discloses a silicon shell protected Escherichia coli multifunctional probe, a preparation method and application of the probe in inflammatory marker detection, the surface of Escherichia coli is sequentially coated with a layer of gold nanoparticles (AuNPs), a layer of silicon dioxide (SiO2) and two layers of quantum dots (QDs), and rapid monitoring of sepsis biomarkers is achieved. The SiO2 layer introduced into the EASi-QDs structure has dual functions of remarkably enhancing the structural stability of bacterial cells and effectively inhibiting the fluorescence quenching effect caused by Au NPs, so that the high sensitivity and accuracy of lateral flow immunochromatography (LFIA) detection are ensured. The EASi-QDs-LFIA has the functions of colorimetric qualitative detection and fluorescent quantitative analysis, and can be used for synchronously detecting two key sepsis markers, namely procalcitonin (PCT) and interleukin-6 (IL-6). The detection limits of the method on PCT and IL-6 respectively reach 29.5 pg / mL and 4.7 pg / mL, which are respectively improved by at least 15 times and 339 times compared with the traditional enzyme-linked immunosorbent assay (ELISA) and gold nano colorimetric method.

The invention relates to the field of biological detection, in particular to a marker and application thereof in construction of a preeclampsia prediction model. The invention provides a marker, which comprises a red blood cell index and an inflammation marker; the red blood cell indexes comprise red blood cell count, hemoglobin, hematocrit, average red blood cell volume, average red blood cell hemoglobin and red blood cell distribution width variable coefficient; the inflammatory markers comprise leukocytes, neutrophils, lymphocytes, monocytes, platelets, eosinophils, platelet hematocrit, a systemic inflammatory response index and a systemic immune inflammatory index. The invention develops an efficient and easily available preeclampsia prediction tool, realizes early recognition and management of preeclampsia, and finally reduces maternal and infant complications.

The invention discloses a chronic disease risk early warning method, system and equipment based on inflammatory markers and a medium, and relates to the technical field of data processing. The method comprises the following steps: acquiring case information and sign information of a target patient, wherein the case information comprises a historical inflammation marker detection record, a chronic disease type and a medication scheme; according to historical inflammatory marker detection records, calculating reference values of multiple inflammatory markers; based on the chronic disease type, screening out an inflammatory marker combination, and correcting the reference value of each inflammatory marker in the inflammatory marker combination based on the medication scheme to obtain an initial early warning threshold group; compensating the initial early warning threshold value group in combination with the physical sign information to obtain a target early warning threshold value group; and collecting a current inflammatory marker detection value, and when any index in the inflammatory marker detection value is greater than or equal to a corresponding index threshold in the target early warning threshold group, generating chronic disease risk early warning information. By implementing the technical scheme provided by the invention, the accuracy of chronic disease risk early warning can be improved.

The present disclosure relates to an ultrasound guided intraarticular administration of a combination of a composition comprising pooled mesenchymal stromal cells, and mid molecular weight hyaluronic acid for treatment of osteoarthritis. The disclosure also provides methods for increasing levels of anti-inflammatory marker and decreasing levels of disease progression marker in a human subject suffering from osteoarthritis through the use of the said combination. The present disclosure accordingly also relates to a kit comprising the said composition and the hyaluronic acid as such for the said use and treatment.

The invention discloses an inflammatory marker and application thereof. The application potential of the TKFC in inflammation detection is disclosed for the first time, the expression condition of the TKFC on a cell membrane based on immune cells is found, the immune cell state and / or the body inflammation condition can be accurately judged, and a new technical means is provided for accurate recognition and monitoring of inflammation.

A system for remote assessment of clinical response and dynamic optimization of the chemotherapy regimen in oncology, consisting of: a device for clinical assessment of patient response, designed as a physical machine structure with a housing for use on the body or at the bedside; a housing-mounted physiological sensor unit configured to record continuous or periodic measurements of heart rate, heart rate variability, respiratory rate, peripheral oxygen saturation, body temperature, physical activity and sleep-related parameters of an oncology patient during chemotherapy; a biochemical sensor unit integrated into the housing, configured to detect biochemical indicators related to response to chemotherapy and toxicity, including inflammatory markers, metabolic indicators, hematological trends or drug-related metabolites; a patient interaction unit configured to receive symptom data reported by the patient, corresponding to treatment tolerability and functional status; an embedded processing unit that is operationally connected to the physiological sensor unit, the biochemical sensor unit, and the patient interaction unit, and is configured to perform signal conditioning, temporal alignment, data integrity verification, and encryption of the acquired patient data; a communication unit that is operationally connected to the embedded processing unit and configured to transmit the processed patient data to a remote processing infrastructure using secure communication protocols; a remote processing system comprising at least one processing unit and a storage unit for storing executable instructions, wherein the processing unit is configured to aggregate longitudinal patient data across chemotherapy cycles, analyze correlations between recorded physiological data, biochemical indicators, patient-reported outcomes, and parameters of chemotherapy administration, and calculate a clinical assessment of response; and A system for interacting with physicians, configured to display the results of the clinical response assessment and generate recommendations for optimizing the chemotherapy regimen, which are subject to review and approval by the physician.

This disclosure relates to the field of computer-aided healthcare, providing a deep learning-based prognostic method, device, and electronic device for AECOPD comorbid with depression. The method includes: acquiring inpatient and post-discharge data of sample patients with AECOPD and depression; inpatient data including examination data upon admission and upon discharge, including peripheral blood serum neuroactive substance data and peripheral blood inflammatory marker data; and post-discharge data including the interval between the first occurrence of CID-C after discharge, the number of CID-C occurrences within 6 months after discharge, and the probability of CID-C occurring within 90 days after discharge; generating training samples based on the inpatient and post-discharge data, and storing the training samples in a training dataset; training a prognostic model using the training dataset; and performing prognostic analysis on target patients with AECOPD and depression using the trained prognostic model. The prognostic method provided by this disclosure can provide rapid and accurate prognosis for AECOPD comorbid with depression.

The application discloses a strain of lactobacillus acidophilus CCFM1356 with anti-glycation and anti-aging functions and a postbiotic thereof, and belongs to the technical fields of microorganisms and medicines. The lactobacillus acidophilus CCFM1356 is preserved in the Guangdong Microbial Culture Collection Center on October 25, 2023, and the preservation number is GDMCC NO: 63926. The paracasei lactobacillus provided by the application can reduce the content of in-vitro fluorescent AGE, the decrease in the activity of HSF, the abnormal mRNA expression of BAX and NFKB1 genes after HSF is damaged. Moreover, the content of fluorescent AGE and inflammatory markers in serum and skin can be reduced, the water content in the matrix layer, the skin elasticity and the collagen content can be improved, and the AGE-RAGE-mediated glycation damage can be reduced. In addition, the bioavailability of peanut skin can be further improved.

The invention relates to a novel lactic acid bacterium, namely, bifidobacterium bifidum P61 KCCM13367P, lactobacillus paracasei P62 KCCM13368P or a mixture of the bifidobacterium bifidum and the lactobacillus paracasei. The novel lactic acid bacteria and mixtures thereof of the present invention change the composition of intestinal microorganisms to inhibit the expression of sarcopenia markers (MuRF-1, MAFbx / Atrogin-1, etc.), increase muscle strength and muscle mass, and promote muscle formation, thereby alleviating sarcopenia. In addition, the present invention ameliorates cognitive disorders by inhibiting behaviors similar to cognitive disorders and modulating the expression of factors (BDNF, IL-10, etc.) associated with said disorders. In addition, the present invention has the effect of treating inflammation by reducing the expression of inflammatory markers (TNF-alpha, IL-6, IL-1beta, and MPO) and increasing the expression of an anti-inflammatory marker (IL-10).

The present invention relates to uses of regulatory T cells manipulated to overexpress CX3CR1. The regulatory T cells induced to overexpress CX3CR1 according to the present invention reduce microglial activation in an LPS-induced neuroinflammation animal model and suppress immune inflammatory responses of activated microglia by inhibiting the expression of pro-inflammatory markers and cytokines in the cortical and hippocampal regions of the brain, and thus can be used for reducing microglial activation or for treating neuroinflammatory diseases or neurodegenerative diseases caused by hyperactivation of microglia in the brain.

A system and method for interactive three-dimensional visualization of physiological stress effects on the human body uses biomarker correlation algorithms to determine physiological responses to physical trauma and toxic stress events. The system receives stress event data, calculates biomarker levels including cortisol, blood pressure, blood sugar, and inflammatory markers, and identifies affected organ systems including cardiovascular, nervous, endocrine, digestive, immune, and reproductive systems. Three-dimensional anatomical models are modified with visual characteristics depicting stress-induced changes based on the biomarker data, including color alterations, geometric deformations, and animated effects. A temporal progression interface enables visualization of immediate, short-term, and long-term physiological effects. Spatial audio synchronized with visual animations provides immersive auditory feedback. Cross-platform rendering modules optimize visualization for mobile devices, desktop computers, tablets, virtual reality headsets, and augmented reality glasses. The system provides for real-time interactive manipulation of anatomical visualizations, particularly for pediatric toxic stress education related to corporal punishment.